Employment and Industry Implications of the Offshore Wind Projects in Rhode Island

Offshore wind farms will have beneficial long-term effects on Rhode Island\u27s industry and employment. While locals have expressed mixed opinions about the wind farm projects, fishermen have been the most concerned. Many of their fears are not founded in the reality of offshore wind farms. Impacts on the fishing industry could be slightly negative during construction with disruption from the pipeline (Becker 2024). After implementation, they should increase biodiversity with the artificial reef effect (Gill et al. 2020; Perry and Heyman 2020; Van Hoey et al. 2021). In the long-term, the fossil fuel industry has and will be more harmful to the fisheries (IPCC 2022). Despite misinformation from the natural gas industry, workers\u27 skills and methods can be transferred to the wind energy (Almegaard 2023, Hattam et al. 2015). In addition, there will be positive long-term economic impacts as employment opportunities grow. Unfortunately, no evidence suggests that plans for diversifying the domestic workforce promote equitable job creation in the local community. Studies into established wind farm projects are needed to understand how they affect Rhode Island industries and employment. It is critical to reference other successful offshore wind farm projects to replicate methods that benefit all areas of the economy. This research suggests that offshore wind farms will positively affect job creation and fisheries in Rhode Island. Still, attention should be paid to equitable hiring practices during future projects to ensure environmental justice

Effect of Capacity Building Interventions on Classroom Teacher and Early Childhood Educator Physical Activity and Fundamental Movement Skills Related Self-efficacy, Knowledge, and Attitudes: A Systematic Review and Meta-Analysis

Generalist teachers and early childhood educators (ECEs) play an important role in promoting physical activity and fundamental movement skills in children. However, teachers face several barriers to promoting physical activity and fundamental movement skills including inadequate training and professional development. Therefore, this study aimed to determine the efficacy of capacity building interventions on teachers’ and ECEs’ physical activity and fundamental movement skills related knowledge, self-efficacy and attitudes. The search revealed 22 studies which reported on 25 unique samples. The most common capacity building intervention component implemented was training/professional development. The results of this study revealed that capacity building interventions are efficacious at improving teachers’ and ECEs’ physical activity related self-efficacy, knowledge, and attitudes. Pre-service teachers and ECEs should be provided training in physical activity and FMS as part of their degrees, and continual professional development and capacity building should be offered to in-service teachers and ECEs to promote physical activity and FMS in children

Salve Regina University Act on Climate: Strategic Plan for the University to Reach State Carbon Neutrality Goals

In order to become more sustainable and meet the mandate set by the 2021 Rhode Island Act on Climate law (RI General Law §42-6.2), Salve Regina University must work to reach net-zero greenhouse gas emissions by the year 2050. Action to meet these standards begins now and must be continually built upon to ensure that Salve Regina University, as leader in Rhode Island, is always working for a more sustainable future. Throughout the Spring 2022 semester, students of the BIO-140: Humans and Their Environment course instructed by Dr. Jameson Chace have researched ways in which Salve Regina can begin on the path to zero greenhouse gas emissions today. By focusing on change in the areas of energy, transportation, food, financial investments, and sequestration, Salve Regina can reduce the greenhouse gas emissions of today for a more sustainable tomorrow. Recommendations are broken into three time periods. Action for today to achieve by 2030 include improving energy efficiency, installing the first electric vehicle (EV) parking/charging stations, increasing carbon sequestration, reducing beef in the campus diet, and assessing the carbon impact of university financial holdings. Actions to be initiated soon and to be achieved by 2040 include shifting away from natural gas heating when system renewals take place, increasing EV parking to meet rising demand, during turnover replace current university vehicles with electric or hybrid, continuing with sequestration efforts on campus, begin phasing out high carbon diet items, and by 2040 the university investment portfolio should be carbon neutral. If carbon neutrality can be reached by 2050 the most challenging aspects of campus life that need to change will require planning now and thoughtful implementation. The class in 2022 envisions a campus in 2050 where solar lights illuminate campus and buildings through the night, all university vehicles and most faculty and staff vehicles are electric and are found charging during the day at solar powered charging stations, dining services in Miley supports community agriculture and includes incentives for meatless and low carbon meal plans, the university has become a leader in low carbon/green market investing demonstrating how careful planning can reap high returns, and carbon sequestration on campus grounds has maximized such that off campus carbon offsets are established with local land trusts to complete the carbon neutrality goals. In doing so no only will the university be recognized as a state-wide leader in climate action, but will also be a global leader in working towards a world that is more harmonious, just, and merciful.https://digitalcommons.salve.edu/bio140_arboretum/1033/thumbnail.jp

Defining elite athletes: Issues in the study of expert performance in sport psychology

© 2014 Elsevier Ltd. Objectives: There has been considerable inconsistency and confusion in the definition of elite/expert athletes in sport psychology research, which has implications for studies conducted in this area and for the field as a whole. This study aimed to: (i) critically evaluate the ways in which recent research in sport psychology has defined elite/expert athletes; (ii) explore the rationale for using such athletes; and (iii) evaluate the conclusions that research in this field draws about the nature of expertise. Design: Conventional systematic review principles were employed to conduct a rigorous search and synthesise findings. Methods: A comprehensive literature search of SPORTDiscus, Academic Search Complete, PsycINFO, and PsycARTICLES was completed in September, 2013 which yielded 91 empirical studies published between 2010 and 2013. The primarily qualitative findings were analysed thematically. Results: Eight ways of defining elite/expert athletes were identified, ranging from Olympic champions to regional level competitors and those with as little as two years of experience in their sport. Three types of rationale were evident in these studies (i.e., "necessity", "exploratory" and "superior"); while findings also indicated that some elite athletes are psychologically idiosyncratic and perhaps even dysfunctional in their behaviour. Finally, only 19 of the 91 included studies provided conclusions about the nature of expertise in sport. Conclusions: This study suggests that the definitions of elite athletes vary on a continuum of validity, and the findings are translated into a taxonomy for classifying expert samples in sport psychology research in future. Recommendations are provided for researchers in this area

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention